치료용 혈장 교환 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Therapeutic Plasma Exchange Market size is expected to reach USD 5.09 Billion in 2034 from USD 2.60 Billion (2025) growing at a CAGR of 7.76% during 2026-2034.

The global therapeutic plasma exchange market is witnessing stable growth due to the increasing prevalence of autoimmune, neurological, and hematological disorders. Conditions such as myasthenia gravis, Guillain-Barre syndrome, and thrombotic thrombocytopenic purpura are driving demand for plasma exchange procedures. Growing awareness about advanced blood purification therapies and their effectiveness in managing complex immune-related diseases is supporting wider adoption across hospitals and specialty care centers worldwide.

Technological advancements in apheresis systems are a major growth driver for the market. Modern devices offer improved safety, efficiency, and reduced procedure time, enhancing patient comfort and clinical outcomes. Additionally, the rising geriatric population, increasing healthcare expenditure, and improved reimbursement policies in developed countries are contributing to market expansion. Hospitals are increasingly investing in advanced critical care technologies to strengthen treatment capabilities.

Looking ahead, the market is expected to benefit from expanding clinical applications and ongoing research in immune-mediated diseases. Growing healthcare infrastructure in emerging economies and rising awareness among healthcare professionals will further create opportunities. With continuous innovation and increasing focus on patient-centered treatment approaches, the therapeutic plasma exchange market is projected to experience steady and sustainable growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease Indication

• Neurological Disorders
• Renal Disorders
• Hematology Disorders
• Others

By End-user

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

COMPANIES PROFILED

• Asahi Kasei Corporation, Baxter International Inc, Terumo Corporation, B Braun SE, Fresenius Kabi AG, SBKawasumi Laboratories Inc, Haemonetics Corporation, Cerus Corporation, Charles River Laboratories, Medica SpA
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease Indication
• 4.2. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Renal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Hematology Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET: BY END-USER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-user
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Disease Indication
  • 6.2.2 By End-user
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Disease Indication
  • 6.3.2 By End-user
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Disease Indication
  • 6.4.2 By End-user
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Disease Indication
  • 6.5.2 By End-user
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Disease Indication
  • 6.6.2 By End-user
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL THERAPEUTIC PLASMA EXCHANGE INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Asahi Kasei Corporation
  • 8.2.2 Baxter International Inc
  • 8.2.3 Terumo Corporation
  • 8.2.4 B. Braun SE
  • 8.2.5 Fresenius Kabi AG
  • 8.2.6 SB-Kawasumi Laboratories Inc
  • 8.2.7 Haemonetics Corporation
  • 8.2.8 Cerus Corporation
  • 8.2.9 Charles River Laboratories
  • 8.2.10 Medica S.P.A